Investment Rating - The investment rating for the company is Neutral, with a target price of HKD 13.15, indicating a potential downside of 11.1% from the current price of HKD 14.80 [1][7]. Core Insights - The company's performance has significantly declined due to a sharp drop in photovoltaic glass prices, resulting in a net loss of RMB 203 million in Q3 2023, marking the first loss since its listing [1]. - Revenue for Q3 2023 was RMB 3.91 billion, down 37% year-on-year and 21% quarter-on-quarter, which was far below market expectations of a profit of RMB 100 million [1]. - The report anticipates that the industry will begin to balance supply and demand due to ongoing production cuts, but significant price recovery will require further reductions in production capacity [1]. - The report suggests that potential government supply-side reforms could accelerate industry consolidation and benefit leading companies with lower energy consumption [1]. Financial Overview - Revenue projections for the company are as follows: RMB 21.524 billion in 2023, RMB 17.881 billion in 2024 (down 16.9% year-on-year), RMB 20.130 billion in 2025, and RMB 23.444 billion in 2026 [2][8]. - Net profit estimates are projected to be RMB 2.760 billion in 2023, RMB 1.114 billion in 2024 (down 59.6% year-on-year), RMB 1.137 billion in 2025, and RMB 2.297 billion in 2026 [2][8]. - The report indicates a significant adjustment in earnings forecasts, with a reduction of 44% for 2024, 49% for 2025, and 29% for 2026 [1]. Market Dynamics - The photovoltaic glass market has seen a drastic price decline, with average prices for 2.0mm and 3.2mm glass dropping by 22% and 11% respectively in Q3 2023 [1]. - Despite production cuts, demand has not met expectations, leading to continued inventory accumulation and further price declines of 8% and 10% since September [1]. - The report highlights that the industry has reduced production capacity by 9% compared to peak levels, with the company itself reducing output by 20% since August [1]. Valuation Metrics - The estimated price-to-book ratio for the company is projected to be between 0.8 and 1.9 times for the next 12 months, reflecting the volatility in earnings and policy expectations [1]. - The report uses a price-to-book ratio of 1.2 times for 2025 as a valuation benchmark, which corresponds to the target price of HKD 13.15 [1].

Investment Rating - The report maintains a "Buy" rating for Rongchang Biopharma (9995 HK) with a target price of HKD 24.00, indicating a potential upside of 45.6% from the current price of HKD 16.48 [1][3][5]. Core Insights - The company's 3Q24 core product sales continue to grow, with significant progress in overseas clinical registrations. The financial forecast for 2024 has been adjusted upwards based on better-than-expected performance in 3Q24 [1][3]. - The report highlights that the sales of the core products, Taitasip and Vidisizumab, are expected to expand further in the domestic market and continue steady progress in overseas clinical trials [1][3]. - The company has sufficient cash reserves of approximately RMB 1.12 billion and a credit line of RMB 2.8 billion to support its operations without needing to secure business development (BD) transactions in the near term [1][2]. Financial Performance Summary - In 3Q24, Rongchang Biopharma reported a revenue of RMB 470 million, a year-on-year increase of 34.6%. The sales of Taitasip reached RMB 270 million, up 43% year-on-year, while Vidisizumab sales were around RMB 200 million, up 25% year-on-year [2][3]. - The net loss for 3Q24 was RMB 290 million, a significant reduction from RMB 430 million in 2Q24. The gross margin improved to 82.1%, an increase of 5.8 percentage points year-on-year [2][3]. - The report projects a 6% increase in the 2024 revenue forecast to RMB 1.74 billion, with Taitasip and Vidisizumab expected to generate sales of RMB 960 million and RMB 760 million, respectively [3][4]. Future Outlook - Key upcoming milestones include the initiation of the second phase of the overseas SLE III trial for Taitasip in 4Q24, with data readout expected in 1H25. The report also notes ongoing registration and critical clinical trials for various indications in China [3][4]. - The report emphasizes the importance of monitoring the registration progress of Vidisizumab for breast cancer and the timeline for overseas submissions based on the progress of the first-line UC III trial [3][4].

Investment Rating - The report maintains a "BUY" rating for RemeGen, indicating a potential return of over 15% over the next 12 months [12]. Core Insights - RemeGen achieved record product sales in Q3 2024, with revenue of RMB467 million, reflecting a 14% quarter-over-quarter and 35% year-over-year increase, driven by strong sales of RC18 and RC48 [1]. - The company narrowed its net loss to RMB291 million in Q3 2024 from RMB432 million in Q2 2024, indicating improved financial performance [1]. - The gross profit margin improved to 82.1% in Q3 2024, up from 78.3% in the first half of 2024, while the SG&A expense ratio decreased to 68.5% [1]. - RemeGen's total revenue for the first nine months of 2024 reached RMB1,209 million, representing a 57% year-over-year growth and aligning with expectations [1]. - The report anticipates continued strong sales momentum into Q4 2024 and beyond, supporting the company's FY24 sales target of over 50% year-over-year growth [1]. Financial Summary - Revenue projections for FY24 are estimated at RMB1,740 million, with a year-over-year growth of 61.7% [2]. - The net profit for FY24 is projected to be a loss of RMB1,268 million, improving to a loss of RMB967 million in FY25 and further narrowing to RMB275 million in FY26 [2]. - R&D expenses are expected to be RMB1,450 million for FY24, remaining stable in FY25, and slightly increasing to RMB1,502 million in FY26 [2]. - The gross profit margin is projected to be 80.31% for FY24, improving to 81.15% in FY25 and 80.81% in FY26 [7]. Valuation - The report revises the DCF-based target price from HK$19.59 to HK$21.09, reflecting a 28% upside from the current price of HK$16.48 [3][4]. - The DCF per share is calculated at HK$21.09, based on a WACC of 12.93% and a terminal growth rate of 2.0% [4][5]. - The market capitalization of RemeGen is approximately HK$8,970.6 million, with an average three-month turnover of HK$42.5 million [3].

Investment Rating - The report maintains an "Accumulate" rating for China Pacific Insurance (2328) and raises the target price to HKD 15.84 per share, corresponding to a 2024 P/B of 1.4 times [3]. Core Views - The company's net profit for the first three quarters of 2024 increased by 38% year-on-year, primarily driven by improved investment profits, while the underwriting side faced pressure [2][3]. - The report highlights a "Matthew Effect" in auto insurance, which has led to an improvement in the combined ratio (COR), while non-auto insurance has been adversely affected by catastrophic claims, resulting in a higher COR [2][3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company reported a net profit of CNY 26.75 billion, a year-on-year increase of 38.0%, mainly due to improved investment profits. The total investment return rate (not annualized) was 4.4%, up by 1.7 percentage points year-on-year [3]. - The underwriting profit decreased by 12.3% year-on-year, attributed to increased catastrophic claims, with the combined ratio rising by 0.3 percentage points to 98.2% [3]. Auto Insurance - Auto insurance premiums grew by 3.2% year-on-year in the first three quarters of 2024, driven by stable growth in the number of insured vehicles. However, the average premium per vehicle decreased by 1.1% year-on-year, although it improved by 0.8% compared to the first half of 2024 [3]. - The auto insurance COR for the first three quarters was 96.8%, a decrease of 0.6 percentage points year-on-year, benefiting from the company's scale effect and effective risk reduction measures [3]. Non-Auto Insurance - Non-auto insurance premium income increased by 5.9% year-on-year, primarily driven by health and liability insurance, which grew by 8.0% and 11.8% respectively. However, agricultural insurance saw a slowdown in growth, increasing by only 1.0% year-on-year [3]. - The underwriting loss for non-auto insurance was CNY 676 million, with a combined ratio of 100.5%, an increase of 1.9 percentage points year-on-year, largely due to natural disasters [3]. Future Outlook - The report anticipates that the recovery in the equity market will serve as a catalyst for improved performance [3].

Investment Rating - The investment rating for Qingdao Bank is "Accumulate" [4][3]. Core Views - Qingdao Bank's net profit growth in Q3 2024 exceeded expectations, while revenue growth slightly declined due to other non-interest income. The bank maintains a double-digit expansion rate and stable asset quality, justifying the "Accumulate" rating [3][4]. Summary by Sections Financial Performance - In Q3 2024, Qingdao Bank's revenue growth was 0.8%, a slight decline compared to Q2. The net interest income, commission income, and other non-interest income grew by 4.8%, -13.1%, and -6.4% year-on-year, respectively. Other non-interest income was the main drag on revenue, likely affected by bond market fluctuations in August. Despite the revenue decline, Q3 net profit growth reached 24.7%, outperforming comparable peers [4]. Asset Quality - As of Q3 2024, the bank's total assets grew by 15.1% year-on-year, with loans increasing by 11.3%. The growth in inclusive small and micro loans was particularly notable, with a year-end balance increase of 8.51 billion yuan, or 25.13%. Deposits grew by 12.9%, improving the deposit-to-liability ratio to 68.5%. The non-performing loan ratio stood at 1.17%, with a coverage ratio of 245.7%, indicating enhanced risk mitigation capabilities [4]. Market Data - The current stock price of Qingdao Bank is HKD 2.74, with a market capitalization of HKD 15,948 million. The stock has traded within a range of HKD 1.84 to HKD 2.97 over the past 52 weeks [5][6].

Investment Rating - The report maintains a "Recommend" rating for China P&C Insurance (02328 HK) with a target price of HKD 15 2 [1] Core Views - China P&C Insurance achieved insurance service revenue of RMB 364 306 billion in 2024Q1-3, a year-on-year increase of 5 3% Net profit reached RMB 26 750 billion, up 38 0% year-on-year, close to the upper limit of the previous performance forecast [1] - The comprehensive cost ratio (COR) for the first three quarters was 98 2%, up 0 3 percentage points year-on-year, mainly due to frequent natural disasters such as typhoons [1] - The total investment yield for the first three quarters was 4 4% (not annualized), an increase of 1 7 percentage points year-on-year, driven by the recovery of the equity market [1] - The company's premium growth accelerated, with motor insurance, health insurance, and liability insurance showing significant growth [1] Business Performance - In 2024Q1-3, the company's original premium income reached RMB 428 330 billion, a year-on-year increase of 4 6% Motor insurance contributed 49 8% of the original premium income, with a year-on-year growth of 3 2% [1] - Non-motor insurance premium income increased by 5 9% year-on-year, with health insurance and liability insurance growing by 8 0% and 11 8% respectively [1] - The COR for motor insurance was 96 8%, within the target range of 97%, while the COR for non-motor insurance was 100 5%, mainly affected by natural disasters [1] Investment Performance - The company's investment income significantly improved, with a total investment yield of 4 4% in 2024Q1-3, up 1 7 percentage points year-on-year [1] - The recovery of the equity market, especially after the "924" market rally, contributed to the increase in investment income [1] - The company's net profit growth was close to the upper limit of the forecast, driven by investment income [1] Financial Forecast - The report revised the EPS forecast for 2024-2026 to RMB 1 51/1 59/1 70, up from the previous forecast of RMB 1 37/1 54/1 70 [1] - The target PB ratio for 2025 is set at 1 1x, corresponding to a target price of HKD 15 2 [1] Market Performance - The current price of China P&C Insurance is HKD 12 08, with a total market capitalization of HKD 268 7 billion and a circulating market capitalization of HKD 83 3 billion [3] - The company's 12-month high/low price range is HKD 14 04/8 08 [3]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 10.14 HKD, based on a current price of 5.79 HKD [1]. Core Insights - The company, Weisheng Holdings, is a leading domestic player in the metering and energy efficiency management sector, with significant growth in revenue and profit since 2022 [2]. - The company has diversified its operations through three main segments: Weisheng Group, Weisheng Information, and Weisheng Energy, which collectively drive its growth [2][4]. - The overseas business has seen a substantial increase, with revenue growing from less than 400 million RMB in 2020 to 1.599 billion RMB in 2023, reflecting a CAGR of 66% [2]. Summary by Sections 1. Leading Supplier in Smart Metering and Energy Management - Weisheng Holdings has established itself as a leader in high-end metering products in China, evolving its business model over the years to focus on smart metering solutions [12]. - The company's ownership structure is concentrated, with the founder holding 53.66% of the shares, allowing for strategic decision-making [15]. - The company has optimized its product structure, leading to rapid revenue growth, particularly in its ADO and overseas segments [18]. 2. Smart Meters: Leading Supplier in Metering - The smart meter segment continues to perform well, with a stable increase in revenue driven by both domestic and international market expansion [29]. - The company has maintained a strong position in bidding for major projects with State Grid and Southern Power Grid, indicating its competitive advantage [25][26]. - The overseas market for smart meters is expanding, with significant growth in revenue and orders, particularly in regions like Latin America and Africa [33][34]. 3. Weisheng Information: Energy IoT Unicorn - Weisheng Information is positioned as a comprehensive solution provider in the energy IoT sector, with a diverse product matrix covering various levels of the energy IoT industry [39]. - The company is focused on enhancing its profitability through continuous innovation and expansion in the energy management space [39]. 4. Financial Projections and Valuation - The company is expected to maintain high growth in its overseas business, with projected net profits of 755 million, 913 million, and 1.159 billion RMB for 2024-2026, respectively [5]. - The report anticipates a steady increase in gross margins as the share of overseas revenue grows, with a target PE of 10X for 2025 [5].

Investment Rating - The report assigns a positive outlook on Standard Chartered PLC with a focus on outperforming the market in the next 12-18 months [6][12][15] Core Insights - Standard Chartered's Q3 2024 revenue and profit exceeded Bloomberg consensus expectations, with a year-on-year revenue growth of 11.4% compared to the expected 7.0% [2][6] - Net interest income grew by 9.1% year-on-year, surpassing the consensus forecast of 7.9%, while other income increased by 14.0%, exceeding the expected 6.3% [2][6] - The bank's net interest margin (NIM) rose by 32 basis points to 1.95%, higher than the expected 1.80% [3][7] - Customer loans and advances grew by 2.2% year-on-year, which was below the expected growth of 3.0%, while customer deposits increased by 5.5%, exceeding the forecast of 4.6% [2][6] Summary by Sections Revenue and Profit - The underlying operating income for Q3 2024 was reported at $4.712 billion, reflecting a growth of 7.0% year-on-year, which is above the consensus estimate [5] - The audited pre-tax profit showed a significant increase of 172.0% year-on-year, surpassing the expected growth of 134.1% [2][5] Credit Quality - Credit impairment losses were reported at $178 million, a decrease of 39.5% year-on-year, which was lower than the consensus estimate of $275 million [3][6] - The non-performing loan (NPL) ratio was reported at 2.27%, down 13 basis points from the previous quarter and lower than the expected 2.67% [3][7] Capital Ratios - The Common Equity Tier 1 (CET1) ratio increased by 30 basis points year-on-year to 14.2%, slightly below the consensus forecast of 14.44% [3][7] - The Return on Tangible Equity (RoTE) rose by 3.8 percentage points to 10.8%, exceeding the expected 10.3% [3][6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 70.08 [1][5][8] Core Views - The company's 3Q24 performance was strong, with total patient visits reaching 1.485 million (+25% YoY, +13.5% QoQ), driven by organic growth and new medical institutions [1] - The company is expected to achieve a 35-40% adjusted net profit growth in 2024, supported by online and offline expansion, same-store growth, and accelerated external expansion [1][5] - The report highlights the company's potential for both organic growth and external expansion, with 19 new medical institutions already established [1][3] Existing Clinics - The company's offline medical business revenue is expected to grow by 35% in 2024, driven by increased doctor numbers in key regions like Shanghai, Beijing, and Guangzhou [2] - The company's self-owned doctor contribution reached 36-37% in 3Q24, with a long-term target of 50%, which is expected to further optimize profit margins [2] New Clinics - The company acquired three new clinics in Suzhou, Kunshan, and Hangzhou in 3Q24, with controllable acquisition costs [3] - New clinics are expected to contribute approximately 10% of the company's revenue in 2024, with a total of 19 new clinics added so far and a full-year guidance of 17-22 new clinics [3] - Overseas expansion is progressing, with Singapore operations gradually ramping up, and further expansion expected in Malaysia, Hong Kong, and Taiwan [3] Policy and Repurchase - The government has introduced frequent policies to encourage traditional Chinese medicine (TCM) development, which benefits the company [4] - The company has conducted continuous share repurchases from January to September 2024, repurchasing 4.36 million shares for HKD 173 million, demonstrating confidence in its long-term growth [4] Financial Forecasts and Valuation - The company's adjusted net profit is expected to grow by 35-40% in 2024, with adjusted EPS projected at RMB 1.74, 2.30, and 2.93 for 2024-2026 [5][9] - The report assigns a 28x PE multiple for 2025, in line with comparable companies, reflecting the scarcity of TCM service providers and policy tailwinds [5] - Revenue is forecasted to grow from RMB 3.138 billion in 2024E to RMB 5.038 billion in 2026E, with net profit increasing from RMB 334.77 million to RMB 665.20 million over the same period [6][12]

Investment Rating - The report maintains a "Buy" rating for China People's Insurance Group [2][6][4] Core Views - The company reported strong performance in the first three quarters of 2024, with insurance service revenue of CNY 403.765 billion, a year-on-year increase of 6.1%, and a net profit attributable to shareholders of CNY 36.331 billion, up 77.2% year-on-year [2][6] - The combined ratio (COR) for property insurance was 98.2%, reflecting a slight year-on-year increase of 0.3 percentage points, indicating a competitive advantage in property insurance [6][2] - The net profit growth was significantly driven by improved investment income, with fair value changes contributing CNY 22.746 billion, an increase of CNY 31.372 billion year-on-year [6][2] Summary by Sections Financial Performance - In the first three quarters of 2024, the company achieved insurance service revenue of CNY 403.765 billion, a 6.1% increase year-on-year, and a net profit of CNY 36.331 billion, a 77.2% increase year-on-year [6][2] - The property insurance COR was 98.2%, with motor insurance and non-motor insurance COR at 96.8% and 100.5%, respectively [6][2] Business Segments - The new business value (NBV) for life insurance grew by 113.9% year-on-year, with net profit reaching CNY 15.582 billion, a 763.7% increase, driven by market recovery and improved investment returns [6][2] - Health insurance net profit was CNY 5.57 billion, up 40.6% year-on-year, indicating continued improvement in profitability [6][2] Investment Outlook - The report forecasts net profits for 2024-2026 to be CNY 39.2 billion, CNY 39.6 billion, and CNY 45 billion, with growth rates of 76%, 1%, and 14% respectively, supported by a recovering equity market [6][2]